Here are 1-3 brief analogies for C4 Therapeutics (CCCC):

1. It's like a CRISPR Therapeutics, but instead of editing genes, C4 Therapeutics develops drugs that specifically *degrade* harmful proteins to treat diseases like cancer.

2. Think of it as the Moderna or BioNTech of drug development, building a platform to create therapies that specifically *destroy* harmful proteins rather than just blocking them.

3. It's a clinical-stage biotech company similar to Amgen or Genentech, but uniquely focused on pioneering a new class of medicines called 'protein degraders' to eliminate disease-causing proteins for cancer and other serious conditions.

• CFT7455: An orally bioavailable MonoDAC degrader targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas.
• CFT8634: An orally bioavailable BiDAC degrader of BRD9 for synovial sarcoma and SMARCB1-deleted solid tumors.
• CFT1946: An orally bioavailable BiDAC degrader targeting V600X mutant BRAF for melanoma, NSCLC, colorectal cancer, and other solid malignancies.
• CFT8919: An orally bioavailable BiDAC degrader targeting EGFR with an L858R mutation in NSCLC.
• RET Degraders: Earlier stage programs developing degraders for the treatment of various cancers.

C4 Therapeutics (CCCC) is a clinical-stage biopharmaceutical company that develops novel therapeutic candidates. As such, it sells primarily to other companies through strategic collaborations rather than directly to individuals or end-users.

Its major customers, in the context of strategic collaborations and potential future revenue streams, are:

• F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (commonly referred to as Roche). Its shares are publicly traded on the SIX Swiss Exchange under the symbol ROG.VX.
• Biogen MA, Inc. (a subsidiary of Biogen Inc.). The parent company, Biogen Inc., is publicly traded on the NASDAQ under the symbol BIIB.
• Calico Life Sciences LLC. Calico is a subsidiary of Alphabet Inc. (GOOGL/GOOG) and does not have its own public stock symbol.

Risk of Clinical Trial Failure and Regulatory Approval

As a clinical-stage biopharmaceutical company, C4 Therapeutics' business model is highly dependent on the successful development and eventual commercialization of its product candidates, which are currently in early stages of clinical trials. The drug development process is inherently uncertain, lengthy, and expensive, with a high risk of failure at any stage. Most drug candidates do not successfully complete clinical trials or obtain the necessary regulatory approvals. Failure to demonstrate safety and efficacy in clinical trials or to secure regulatory approval from agencies such as the FDA would severely impact the company's ability to generate revenue and continue operations.

Risk of Financial Sustainability and Need for Additional Funding

C4 Therapeutics is a clinical-stage company that has a history of substantial losses and currently generates no revenue from product sales. The company anticipates continued losses as it advances its product candidates through clinical development. Its operations are heavily reliant on external funding, including equity offerings and revenue from collaborations. The inability to raise substantial additional capital on acceptable terms, or at the times required, poses a significant financial risk and could severely impact its research and development activities and overall business sustainability.

Risk from Intense Competition

The biopharmaceutical industry, particularly in areas like oncology and neurodegenerative conditions, is highly competitive. C4 Therapeutics' novel therapeutic candidates, if successfully developed and approved, will face significant competition from existing treatments, as well as from other companies developing similar or alternative protein degradation therapies and traditional approaches to cancer treatment. This competition could limit market acceptance and the commercial success of its product candidates.

C4 Therapeutics (CCCC) develops therapeutic candidates for various cancers. The addressable markets for their main products or services are as follows:

• CFT7455 (targeting IKZF1 and IKZF3 for Multiple Myeloma and Non-Hodgkin Lymphomas, including Peripheral T-cell Lymphoma and Mantle Cell Lymphoma):
  • Multiple Myeloma: The global multiple myeloma market size was valued at approximately USD 29.24 billion in 2025 and is projected to reach USD 44.19 billion by 2034, with a CAGR of 6.10% during the forecast period. North America dominated this market with a share of 58.28% in 2025. Another source states the global multiple myeloma market size was USD 26.07 billion in 2024 and is expected to grow to USD 38.39 billion in 2029 at a CAGR of 8.1%. The U.S. multiple myeloma market is estimated to have around 35,730 new cases diagnosed in 2023.
  • Non-Hodgkin Lymphoma (NHL): The global non-Hodgkin lymphoma treatment market size was valued at USD 11.59 billion in 2025 and is projected to grow to USD 19.44 billion by 2034, exhibiting a CAGR of 6.25%. North America held the largest market share of 49.35% in 2025. Another report estimates the global NHL therapeutics market size was USD 10.99 billion in 2025 and is predicted to increase to approximately USD 20.94 billion by 2034, expanding at a CAGR of 7.43%. The global non-Hodgkin lymphoma therapeutics market size was valued at USD 9.14 billion in 2022 and is expected to grow at a CAGR of 7.95% from 2023 to 2030.
  • Peripheral T-cell Lymphoma (PTCL): The global peripheral T-cell lymphoma treatment market is projected to grow from USD 679.5 million in 2025 to USD 1,294.9 million by 2035, at a CAGR of 6.7%. The market for peripheral T-cell lymphoma across the top 7 markets (US, EU4, UK, and Japan) reached USD 637.1 million in 2024 and is expected to reach USD 1,051.2 million by 2035. The total Peripheral T-Cell Lymphoma Therapeutics Industry Market Size in the 7MM (United States, EU4, UK, and Japan) was estimated to be approximately USD 680 million in 2020. In 2023, there were approximately 12,600 new cases of Peripheral T-cell Lymphoma (PTCL) in the U.S.
  • Mantle Cell Lymphoma (MCL): The global Mantle Cell Lymphoma therapeutics market size was valued at USD 1.45 billion in 2025 and is projected to grow to USD 2.78 billion by 2034, exhibiting a CAGR of 7.8%. North America is the largest market for MCL therapeutics, accounting for approximately 45% of the global market share. Another source states the global Mantle Cell Lymphoma market reached US$ 2.1 billion in 2022 and is expected to reach US$ 2.9 billion by 2030.
• CFT8634 (targeting BRD9 for Synovial Sarcoma and SMARCB1-deleted solid tumors):
  • Synovial Sarcoma: The global synovial sarcoma treatment market size is estimated to be valued at USD 715 million in 2025 and is expected to reach USD 1.25 billion by 2032, exhibiting a CAGR of 8.5%. Another report indicates the global synovial sarcoma market is projected to grow to an estimated USD 420 million by 2034, up from USD 245 million in 2024, at a CAGR of 6.8%. The global synovial sarcoma therapeutics market was valued at US$ 47.6 million in 2022 and is expected to reach US$ 139.8 million by 2031. North America accounted for the largest revenue share in 2022.
  • SMARCB1-deleted solid tumors: Specific addressable market size for "SMARCB1-deleted solid tumors" was not found directly in the search results.
• CFT1946 (targeting V600X mutant BRAF to treat Melanoma, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, and other solid malignancies):
  • Melanoma: The global melanoma therapeutics market size was valued at USD 5.95 billion in 2023 and is expected to reach USD 14.89 billion by 2032, growing at a CAGR of 10.59%. The U.S. melanoma therapeutics market was valued at USD 0.52 billion in 2023 and is expected to reach USD 1.14 billion by 2032. North America dominated the melanoma therapeutics market with around 40% market share in 2023. The US melanoma market is projected to grow from USD 1.68 billion in 2025 to USD 2.96 billion by 2035.
  • Non-Small Cell Lung Cancer (NSCLC): The global non-small cell lung cancer market was estimated at USD 20.2 billion in 2024. It is expected to grow to USD 53.9 billion in 2034, at a CAGR of 10.4% from 2025 to 2034. North America dominated the global market with a market share of 44.4% in 2024. The U.S. non-small cell lung cancer market was valued at USD 8.2 billion in 2024. Another source states the global non-small cell lung cancer therapeutics market size was valued at USD 38.49 billion in 2025 and is projected to grow to USD 74.99 billion by 2034. The NSCLC market in the 7MM (US, EU4, UK, and Japan) is projected to reach approximately USD 65 billion by 2034.
  • Colorectal Cancer: The global colorectal cancer market size was evaluated at USD 13 billion in 2023 and is slated to hit USD 20 billion by the end of 2032 with a CAGR of nearly 5% between 2024 and 2032. North America accounted for about 64.3% of the global colorectal cancer market size in 2023. The global colorectal cancer market is estimated to be valued at USD 13.74 billion in 2025 and is expected to reach USD 19.08 billion by 2032. The U.S. colorectal cancer therapeutics market size was estimated at USD 3.42 billion in 2024 and is predicted to be worth around USD 5.43 billion by 2034.
• CFT8919 (targeting EGFR with an L858R mutation in NSCLC):
  • This product targets a specific mutation within Non-Small Cell Lung Cancer (NSCLC). The market size for NSCLC is detailed above, but a specific addressable market size solely for EGFR L858R mutation within NSCLC was not explicitly identified as a separate market.
• Earlier stage programs (comprising RET degraders for the treatment of various cancers):
  • Specific addressable market size for "RET degraders" or "RET fusion cancer" was not found directly in the search results.

C4 Therapeutics, Inc. (CCCC) is a clinical-stage biopharmaceutical company with several potential drivers for future revenue growth over the next 2-3 years, primarily centered on the advancement of its pipeline and strategic collaborations.

The key drivers of future revenue growth include:

1. Advancement and Potential Commercialization of Cemsidomide in Multiple Myeloma: Cemsidomide, the company's lead product candidate, has entered a Phase 2 registrational trial (MOMENTUM) for relapsed/refractory multiple myeloma, with patient dosing initiated in early 2026. Topline data from the MOMENTUM study are anticipated in the second half of 2027. Additionally, a Phase 1b study evaluating cemsidomide in combination with Pfizer’s elranatamab is expected to commence in Q2 2026, forming part of a differentiated registrational pathway. Management projects an initial revenue opportunity for cemsidomide in multiple myeloma ranging from $2.5 billion to $4 billion.
2. Growth in Collaboration Revenue and Achievement of Milestone Payments: C4 Therapeutics benefits from strategic collaborations with companies such as F. Hoffmann-La Roche Ltd and Biogen MA, Inc. The company has reported stronger-than-expected collaboration revenue. For instance, a $2 million milestone payment was received from Biogen in January 2026, associated with the advancement of BIIB145 (a BTK degrader) into clinical development. The prioritization of a KRAS project under a collaboration with Merck KGaA also contributed to an increase in revenue for Q4 2025.
3. Progression of Other Clinical-Stage Programs: The advancement of other clinical candidates, such as CFT8919 and CFT1946, represents additional potential revenue drivers. CFT8919, an EGFR L858R degrader for non-small cell lung cancer (NSCLC), is currently in a Phase 1 study, with data expected in Q1 2026. The company continues to invest in its broader pipeline of degraders targeting various oncology and non-oncology indications, which could lead to future product launches or new collaboration opportunities.

Share Issuance

• In January 2024, C4 Therapeutics received proceeds from the sale of common stock to a subsidiary of its partner Betta Pharmaceuticals.
• The company also received proceeds from the settlement of shares under its at-the-market (ATM) offering arrangement in January 2024.
• During the fourth quarter of 2023, C4 Therapeutics generated $72 million of new equity capital, net of commissions and fees, by selling approximately 13.7 million shares under its ATM facility.

Inbound Investments

• C4 Therapeutics entered into new collaborations in 2023.
• In December 2023, C4 Therapeutics and Merck entered a collaboration for degrader antibody conjugates, with C4T receiving a $10 million upfront payment in January 2024 and eligibility for approximately $600 million in milestone payments.
• Around January 2024, C4 Therapeutics received a $25 million equity investment from a subsidiary of Betta Pharmaceuticals.

Capital Expenditures

• C4 Therapeutics expects its cash, cash equivalents, and marketable securities to be sufficient to fund planned operating expenses and capital expenditures into 2027.
• The company reported capital expenditures of $11K in Q4 2025, which were directed towards funding long-term assets and infrastructure.
• Capital expenditures were $14K in Q3 2025.